Therapeutic Drugs and Delivery Strategies for Gastrointestinal Diseases
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Clinical Pharmaceutics".
Deadline for manuscript submissions: 30 April 2025 | Viewed by 1573
Special Issue Editors
Interests: targeted drug delivery; peptide-drug-conjugates; Cellular immunotherapy; animal models of cancer
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Ailments of the gastrointestinal (GI) tract are commonly reported across the world in both adult and pediatric populations. The GI tract is home to a complex system of immune cells collectively called the mucosal immune system. In both states of health and disease, the mucosal immune system plays a crucial role in how the gastrointestinal tract operates on a daily basis. The therapies and pharmacologic agents used to treat mucosal diseases, such as inflammatory bowel disease, Celiac disease, and eosinophilic and non-eosinophilic diseases, have improved in recent years. These newer agents, drug dosages, therapy forms, and therapeutic preparation still constitute areas of exploration and discovery. As science advances, the clinical application and placement of these therapies will be vital to understand as we begin to tailor individual therapy to each patient’s disease.
Prof. Dr. Michael A. Firer
Dr. Hengqi Zheng
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- targeted therapy in drug delivery
- biologic therapies in inflammatory bowel disease (e.g., special dosages, administration and delivery)
- biologic therapies in eosinophilic esophagitis (e.g., special dosages, administration and delivery)
- eosinophilic gastrointestinal disease
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
